Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)

Maria Teresa Voso, Emanuele Angelucci, Valeria Santini, Anna Angela Di Tucci, Giulia Quaresmini, Carlo Finelli, Antonio Volpe, Giovanni Quarta, Flavia Rivellini, Grazia Sanpaolo, Daniela Cilloni, Flavia Salvi, Giovanni Caocci, Alfredo Molteni, Daniele Vallisa, Susanna Fenu, Lorenza Borin, Giancarlo Latte, Giuliana Alimena, Alfonso PiciocchiPaola Fazi, Marco Vignetti, Sante Tura

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

68 Citazioni (Scopus)

Abstract

In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaEuropean Journal of Haematology
DOI
Stato di pubblicazionePubblicato - 2014
Pubblicato esternamente

Keywords

  • Chelation Therapy
  • Deferasirox (DFX)
  • Iron Chelation
  • Iron Overload
  • Myelodysplastic Syndromes
  • Safety
  • Serum Ferritin

Fingerprint

Entra nei temi di ricerca di 'Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial)'. Insieme formano una fingerprint unica.

Cita questo